Kornimate/medical-research-clean huggingface dataset:
a registry to capture patient outcomes with kras g12r altered advanced pancreatic ductal adenocarcinoma treated with mek inhibitor-based combination therapy

Conditions: Pancreatic Ductal Adenocarcinoma

Summary: this is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (meki) -based treatment strategies and the feasibility of administering meki combination therapies to patients with kras g12r mutated advanced pancreatic ductal adenocarcinoma (pdac).

patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well kras g12r pancreatic patients respond to meki-based combination matched therapy. patient outcome parameters including but not limited to tumor response, patient survival, and toxicity will be analyzed. moreover, metrics will be collected to ascertain whether a future clinical trial involving a meki-based combination therapy is feasible to carry out.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years. 2. diagnosis of advanced pancreatic ductal adenocarcinoma as determined by the treating physician or tumor board. 3. tumor must have kras g12r mutation, as determined by a next generation sequencing (ngs) panel or circulating tumor dna panel of choice of the treating physician. 4. ability to understand a written informed consent document and the willingness to sign it. exclusion criteria: 1. age \<18 years. 2. primary cancer diagnosis other than advanced pancreatic ductal adenocarcinoma 3. tumor does not have a kras g12r mutation.

Keywords: pancreatic ductal adenocarcinoma kras g12r mutation precision medicine retrospective chart review prospective chart review
impact of whey protein supplementation on body weight and metabolic parameters of bariatric patients

Conditions: Bariatric Surgery; Sarcopenia

Summary: obesity is a metabolic disorder, characterized by an increase in the body's fat mass, which will reflect an increase in total body weight. in brazil, overweight accounts for 53.8% of the population, and of these 18.9% are obese. surgical treatment is currently the most successful method for weight loss in patients with grade iii obesity and reduced associated morbidities. the general objective is to evaluate genetic, inflammatory, and dietary factors that would influence weight loss and the appearance of protein deficiency or sarcopenia in patients undergoing bariatric surgery and to evaluate the effects of protein supplementation for 8 weeks after the 18th postoperative month in the parameters evaluated. the study has a randomized, placebo-controlled, double-masked model. the patients will be selected in two bariatric surgery services accredited by the brazilian health unic system (sus) in the city of belo horizonte, brazil. the project has already been approved by the brazilian ethics committee conep/ufmg by nº. 75415317.8.0000.5149. patients of both sexes over 20 years of age will be included, attending the hospitals of the project with regular follow-up in the postoperative period. data on anthropometry, body composition, muscle strength, energy expenditure, and inflammatory profile will be collected. the data will be correlated with the evaluation of the presence of genetic polymorphisms.

specific objectives: it is also objective to evaluate: * to observe the food consumption between 18 and 24 months of surgery with respect to protein and caloric intake; * evolution of weight loss, lean mass, fat mass and metabolic rate before and after supplementation with wp or placebo; * changes in protein status (assessed by muscle strength and serum levels of total protein, albumin, prealbumin, ferritin, hemoglobin) before and after supplementation with wp or placebo * the inflammatory blood profile (assessed by cytokine levels and before and after supplementation with wp or placebo). * the influence of the rs9939609 polymorphism of the fto gene on the nutritional status, biochemical and inflammatory parameters in the postoperative (after 18 months) of surgery;

Eligibility criteria:
inclusion criteria: * patients of both sexes over 20 years of age * patients with regular follow-up in the postoperative period. exclusion criteria: * patients with debilitating chronic diseases * severe vomiting * submitted to other surgical procedures before 18 months of surgery * patient with prostheses * use or introduction of drugs immunosuppressants or affecting metabolism

Keywords: obesity sarcopenia bariatric surgery protein
effectiveness of scaling and root planing in deeper pockets

Conditions: Periodontal Disease; Periodontitis

Summary: this study will retrospectively evaluate the outcomes of scaling and root planing over a two year time period. the study will focus specifically on the effectiveness of srp in pockets with an initial pre-treatment pocket probing depth of ≥ 5 mm and ≤ 8 mm. the study will also examine the response to srp of all initial pocket depths, i.e., those ppd that fall below or above those in the indicated range, to verify the findings of previous studies.


Eligibility criteria:
inclusion criteria: * all patients treated by dental students who have the required data * 14 or more permanent teeth * have at least 2 molars (excluding third molars) exclusion criteria: * all third molars and second molars next to a partially impacted third molar * smokers * diabetes * immunocompromised patients (hiv/aids; chemotherapy; systemic steroid therapy, etc.) * pregnancy during treatment or during the follow-up periods * diagnosis of alzheimer's or dementia * diagnosis of oral mucous membrane disease (bmmp, lupus, erosive lichen planus, etc.) * patients that have received periodontal surgery following srp
early progressive strength exercise for treatment of acute achilles tendon rupture.

Conditions: Achilles Tendon Rupture

Summary: the purpose of this trial is to investigate the efficacy of standard care versus standard care combined with an early progressive exercise program in improving the function of the tendon and leg muscles after non-surgical treated achilles tendon rupture

acute achilles tendon rupture often results in long-term muscular deficits. patients struggle to return to work and sports with high load on the lower leg. early functional rehabilitation has shown good results, but research on resistance exercise is scarce and the reporting of the specifics of the exercises are poor.

Eligibility criteria:
inclusion criteria: * acute total achilles tendon rupture treated non-surgically * diagnosed within 3 days (of their injury) * age 18 - 65, able and willing to participate in the intervention * able to speak and understand danish exclusion criteria: * achilles tendon rupture close to insertion on calcaneus or in the musculo-tendinous junction of the triceps surae * previous achilles tendon rupture or other conditions in either leg causing lower leg disability (pain, deficits in strength or range of movement) * treated with fluoroquinolons or corticosteroids within the last 6 months * diabetes or rheumatic diseases * severe medical illness: asa score higher than or equal to 3. (asa: american society of anesthesiologists physical status classification system)

Keywords: achilles tendon rupture early functional rehabilitation resistance training
the evaluation of bococizumab (pf-04950615; rn316) in reducing the occurrence of major cardiovascular events in high risk subjects

Conditions: Cardiovascular Disease

Summary: this study evaluates the pcsk9 inhibitor, bococizumab (pf-04950615;rn316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and unstable angina requiring urgent revascularization in high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of ldl-c \>/= 100 mg/dl (2.6 mmol/l) or non-hdl-c \>/=130 mg/dl (3.4 mmol/l).

the trial was terminated prematurely on november 1, 2016, due to the emerging clinical profile and the evolving treatment and market landscape for lipid-lowering agents. these indicated that bococizumab was not likely to provide value to patients, physicians, or shareholders. the decision was not based on a recommendation by the independent data monitoring committee to stop the program.

Eligibility criteria:
inclusion criteria: * must be on background lipid lowering treatment. * must be at high risk of a cv event. * must have an ldl c \>/=100 mg/dl (2.6 mmol/l) or non hdl c \>/=130 mg/dl (3.4 mmol/l). exclusion criteria: * planned coronary (pci or cabg) or other arterial revascularization. * new york heart association class iv congestive heart failure or left ventricular ejection fraction \< 25% by cardiac imaging. * chronic renal insufficiency with creatinine clearance of \<30 ml/min/1.73m\^2 by mdrd formula or with end state renal disease on dialysis. * history of hemorrhagic stroke. * prior exposure to bococizumab or other investigational pcsk9 inhibitor.

Keywords: myocardial infarction stroke hyperlipidemia
the use of the uscom device in addition to cardiac ultrasound in patients undergoing treatment for undifferentiated shock

Conditions: Shock

Summary: currently, bedside ultrasound (us) is performed routinely in emergency department (ed) patients with undifferentiated shock to help guide resuscitation. previously, it has never been possible to measure cardiac output on patients in the ed. our clinical question looks at whether the uscom device gives clinically relevant information in addition to ed cardiac us in patients with shock.


Eligibility criteria:
inclusion criteria: * patients in shock, as defined by systolic blood pressure less than 95 mmhg or shock index (heart rate/systolic blood pressure) greater than 0.9 exclusion criteria: * less than 18 years old * pregnant * patients in shock due to trauma

Keywords: shock uscom cardiac ultrasound emergency department
treatment of salivary gland hypofunction with neuro- electrostimulation

Conditions: Xerostomia; Polypharmacy; Sjögren's Syndrome

Summary: the objective of the study is to evaluate with clinical parameters the performance of saliwell crown as a neuro-electrostimulator of the submandibular and sublingual salivary glands in hypofunction status due to polypharmacy or sjögren's syndrome in patients with symptoms of xerostomia.


Eligibility criteria:
inclusion criteria: * age range between 18 and 75 years of age * clinical symptoms of xerostomia * difference in whole salivary flow between resting and stimulating conditions * patient asa type i to iii * absence of at least one mandibular third molar inferior, but at least partially dentated in the mandible exclusion criteria: * patients with antimicrobial treatments in the three previous months * smokers * intake of bisphosphonates * limitation of mandibular opening * interoclusal distance smaller than 10 millimetres * lack of adequate bone availability for implant placement
better days, better nights: treatment for sleep difficulties (telephone coached)

Conditions: Sleep Disorder

Summary: the purpose of the strongest families (formerly family help program)is to evaluate the effectiveness of the strongest families distance intervention compared to usual or standard care that is typically provided to children with mild to moderate sleep onset latency and/or bedtime resistance difficulties. this is a single-centre trial based at the iwk health centre. the primary outcome is change in sleep patterns (sleep onset latency and/or bedtime resistance).

the purpose of the family help sleep program is to deliver, primary care mental health services to children and their families in the comfort and privacy of their own home. approximately 80 children (6-12 years of age)suffering from mild to moderate sleep onset latency and/or bedtime resistance will be randomized. the intervention is delivered from a distance, using an educational handbook and telephone consultation with a trained paraprofessional "coach" who is supervised by a licensed health care professional. the telephone coach delivers consistent care based on written protocols, with on-going evaluation by a professional team.

Eligibility criteria:
inclusion criteria: * children 5-12 years of age * attending grades primary-6 (elementary school) * sleep onset latency and/or bedtime resistance * speak and write english * provides parental authorization * has access to telephone in home exclusion criteria: * any mental health disease with the exclusion of disruptive behavior disorder * neurological conditions * moderate to severe cognitive impairment * has received a behavioral intervention for sleep difficulties in the past 6 months * nocturnal enuresis * sleep apnea * co-sleeping

Keywords: sleep onset latency bedtime resistance
use of a vibration tool for postoperative pain control in distal radius fractures

Conditions: Distal Radius Fracture; Radius Fracture Distal; Radius; Fracture, Lower or Distal End; Postoperative Pain

Summary: the purpose of this research study is to determine if using a vibration tool improves pain control after surgical treatment of distal radius fracture. additionally, the investigators would like to determine if this tool has any impact on consumption of pain medications postoperatively.

traditionally, occupational therapists have utilized vibration for sensory re-education in compression neuropathies and peripheral nerve injuries. vibration is also commonly used for desensitization of hypersensitivity following amputation, crush injury, and for hypersensitive scarring. since the vibration tool is readily available in the hand therapy clinic, vibration analgesia should be further explored in the hand clinic to help reduce pain. vibration is a simple, and non-invasive, tool and would be easy, economical, and practical to implement into the hand clinic for postoperative pain control. this research project will evaluate whether vibration can be a useful adjunct to current postoperative pain modalities. with a multidisciplinary approach, the investigators hope to highlight the use of non-opioid modalities of pain control in distal radius fractures and believe that the findings from this study may apply to other painful conditions of the hand as well.

Eligibility criteria:
inclusion criteria: * patients with a distal radius fracture who have undergone an open reduction and internal fixation using a volar fcr approach with a single volar plate * patients who can read, write, and follow direction in english * willing to undergo occupational therapy at northwestern medicine's hand surgery clinic exclusion criteria: * patients undergoing oncologic surgery * patients who undergo simultaneous surgery such as open carpal tunnel * patients who only require closed reduction of distal radius fractures * operative patients that require dorsal plate fixation or separate radial styloid plate fixation
effectiveness and tolerability of phentermine in patients under bariatric surgery

Conditions: Obesity; Morbid Obesity; Bariatric Surgery; Non-alcoholic Fatty Liver; Weight Loss

Summary: surgical management of morbid obesity is increasingly frequent. a low-calorie diet is recommended with the main goal of reducing intrahepatic fat infiltration, fat tissue and making easier the surgery. information the use pharmacological interventions during the preoperative period in this population are rare.

this is a randomized, control trial to investigate the effect and safety of phentermine in patients with obesity who need a bariatric surgery (bmi \>35 kg/m2 with comorbidities or bmi \> 40 kg/m2). screening will be made to select eligible participants before intervention. participants were randomly assigned to one of two groups (low-calorie diet + phentermine 15 mg or low-calorie diet + placebo) for therapies during 6 weeks. anthropometric measurements (weight, body composition, body mass index and waist-hip index), serum metabolic profile (glucose, total cholesterol, hdl-c, ldl-c, triglycerides, and homa-ir) markers of inflammation (il-1, il-6 and pcr) and hepatic ultrasound will be measured 2 times for each participant. surgical complications (anastomosis filtration, intestinal obstruction or stenosis, need to perform open surgery and mortality) will be evaluated. adverse events associated with phentermine (blood pressure, cardiac frequency, headache, gastrointestinal symptoms, euphoria, anxiety and insomnia) will be collected.

Eligibility criteria:
inclusion criteria: * women and men * \>18 years and \<55 years old. * diagnosis of obesity grade ii with comorbidities * diagnosis of obesity grade iii with or without comorbidities * approved to bariatric surgery by an interdisciplinary committee * having signed the informed consent form exclusion criteria: * use of addictive substances * inability or lack of understanding to achieve lifestyle and behaviour changes * mental disease * severe pulmonary disease * giant hiatal hernia, gastric or duodenal ulcer * unstable coronary artery disease * portal hypertension or esophageal varices * surgical or anesthetic high risk

Keywords: obesity obesity treatment non-alcoholic fatty liver weight loss
evaluation of spa therapy in the treatment of fibromyalgia

Conditions: Fibromyalgia; Rheumatism, Muscular

Summary: fibromyalgia is a common health problem that causes widespread pain and tenderness (sensitive to touch). the pain and tenderness tend to come and go, and move about the body. there is no cure for fibromyalgia. complementary and alternative therapy such as acupuncture, chiropractic and massage therapy, can be useful to manage fibromyalgia symptoms. many of these treatments have not been well tested in patients with fibromyalgia. fibromyalgia affect 3 to 4% of the general population and 14 % of patients with rheumatologic disease. fibromyalgia is most common in women 90 % in many studies. it most often starts in middle adulthood. a chronic evolution occured for fibromyalgic patients with a major alteration of quality of life. thermalgi is a randomized, multicentre, open label trial wich aims to evaluate the effects of spa therapy in rheumatologia on evolution of disability in daily life of patients with fibromyalgia.

thermalgi is a controlled, randomized, multicentre, open label trial wich aims to evaluate the effects of spa therapy in rheumatologia on evolution of disability in daily life of patients with fibromyalgia. patients with fibromyalgia (american college of rheumatology criteria) and a fiq score (fibromyalgia impact questionnaire) \> 39 will be randomized.

Eligibility criteria:
inclusion criteria: * both sexes, more than 18 years old patients * available for a spa treatment in rheumatology during 18 days (immediate or late spa) and a follow-up period of 12 months * with fibromyalgia ( acr criteria 2010) for at least 1 year and with a stable treatment for at least 3 months * with a fiq score \> or = 39 (fibromyalgia moderate to severe) * voluntary to participate to the study, informed consent form signed after appropriate information * affiliation to the social security system or equivalent exclusion criteria: * contra-indication of spa treatment (cancer in progress, psychiatrics disorders, immunodeficiency) * no previous spa treatment in rheumatology within 1 year prior to inclusion * substantial variation of the therapeutic coverage in the previous 3 months the inclusion (change of medicinal class, starting up of a réentrainement in the effort or a cognitivio-behavioral technique) * subject with an other chronic severe disease (severe asthma, severe cardiac insuffisiancy, respiratory, renal or liver failures, evolutive rheumatic disease, inflammatory colitis...) * subject participating to an other clinical study inerventionnal * pregnancy, parturient or breast feeding * no psychiatric illness or social situation that would preclude study compliance

Keywords: fibromyalgia rheumatism fatigue syndrom pain spa treatment in rheumatology
contribution of 18fdg pet-scan in tumour volume determination in patients operated of breast cancer

Conditions: Infiltrating Ductal Carcinoma

Summary: use of positron emission tomography (pet) in determination of functional tumour volume can provide usable information for radiotherapy to define the irradiated volume. to determine the best tumour volume measure method, the investigators have chosen as model the breast cancer which allows us to study a stationary or moving organ by the patient position and belonging to a primary surgery. the used methodology is based on lesion volume measure in preoperative time, obtained with pet, and on the measure of specimen volume by the anatomic laboratory after surgery. this study's main objective is to compare this two measure of tumour size and secondarily to compare tep with or without respiratory gating. the pet-scan is achieved with fdg, under his french permission marketing, and acquire in 3 times: a whole body acquisition in supine position, follow by a centered tumour acquisition with respiratory gating, then an acquisition in prone position to immobilise the lesion. this study is monocentric and descriptive. it provides to include 30 patients in 1 year.

the use of positron emission tomography (pet) in determination of functional tumour volume may pose two major problems especially for the exact delineation of tumour contours: * respiratory movements, when the tumour is thoracic, may induce an overestimation * the pet's low spatial resolution, linked to the emission of photons the usual method to define tumour contours result of three types of delineation usually used: the visual contouring, the segmentation based on an activity threshold fixed, and the segmentation with adaptive thresholding.

Eligibility criteria:
inclusion criteria: * invasive non-lobular breast cancer, histologically proven by biopsy * tumour t2 - t3 regardless of nodal status, stemming from a primary surgery, in whom fdg-pet is performed for staging * age greater than or equal to 18 years * good condition: who lower 2. * women receiving effective contraception throughout the duration of treatment and 3 months after cessation of treatment, * patient has signed informed consent exclusion criteria: * carcinoma other than breast ductal carcinoma. * patients for whom no target tumor is assessable. * patients for whom surgery first of their breast cancer is not indicated (tumor spread, metastasis, general health, co-morbidities). * pregnant women, or likely to be during breastfeeding. * major protected (under supervision and under guardianship) * failure to submit to medical supervision of the study for reasons of geography, social or psychological * incomplete tumor resection

Keywords: positron-emission tomography pet scan fdg suv invasive breast cancer surgery compare tumor measurement